Platelet-rich plasma for treatment of chronic proximal hamstring tendinopathy.
Michael J AuriemmaAdam S TenfordeAdam HarrisKelly C McInnisPublished in: Regenerative medicine (2020)
Aim: To determine whether platelet-rich plasma (PRP) can successfully treat symptoms associated with proximal hamstring tendinopathy. Materials & methods: Charts were retrospectively reviewed of patients with a diagnosis of chronic proximal hamstring tendinopathy who underwent an ultrasound-guided leukocyte-rich PRP injection to assess reported outcomes at baseline and final follow-up post-intervention. Results: In 22 patients with a mean age of 48.7 years and mean symptom duration of 26.5 months, mean Numeric Pain Rating Scale and Victorian Institute of Sport Assessment Scale for Proximal Hamstring Tendinopathy subscores demonstrated statistically significant improvements (p < 0.05) at a mean of 7.91 months follow-up. Sixty-eight percent of patients demonstrated ≥50% reduction of pain. Conclusion: Pain and functional outcomes improved following injection of PRP.
Keyphrases
- platelet rich plasma
- ultrasound guided
- chronic pain
- anterior cruciate ligament reconstruction
- anterior cruciate ligament
- pain management
- neuropathic pain
- end stage renal disease
- randomized controlled trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- type diabetes
- prognostic factors
- adipose tissue
- spinal cord injury
- fine needle aspiration
- patient reported
- weight loss
- skeletal muscle
- glycemic control